The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).
 
Eric S. Schaefer
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - Abbvie; F. Hoffmann LaRoche; Genentech; Janssen; Novartis; Pfizer
 
D. Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anchiano; Apollomics; AstraZeneca; bio-thera; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Elevation Oncology; EMD Serono; GlaxoSmithKline; Helsinn Therapeutics; Inivata (Inst); Janssen; Kestrel Labs; Lilly; Mersana; Nuvalent, Inc.; OnKure; Pfizer; QiLu Pharmaceutical; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Takeda
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Janssen; Kirin Pharmaceuticals; Lilly Japan; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Alona Zer
Stock and Other Ownership Interests - NIxio
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Tatiana Hernandez Guerrero
No Relationships to Disclose
 
Jair Bar
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; F. Hoffmann LaRoche; MSD; Novartis; Takeda
Research Funding - Abbvie (Inst); AstraZeneca (Inst); F. Hoffmann LaRoche (Inst); MSD (Inst); Novartis (Inst); Takeda (Inst)
 
Yusuke Okuma
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Lilly
Research Funding - Abbvie (Inst); Chugai Pharma (Inst)
 
Julio Antonio Peguero
Employment - Oncology Consultants
Leadership - Oncology Consultants
Stock and Other Ownership Interests - Oncology Consultants; Roche; Spectrum Pharmaceuticals; Tersera; zogen
Honoraria - Agendia; Guardant Health; Tempus
Consulting or Advisory Role - Tersera
Speakers' Bureau - Agendia; Guardant Health; Tempus
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Dizal Pharma (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Genentech/Roche (Inst); Immatics (Inst); ImmunityBio (Inst); Immutep (Inst); IncMed (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Kechow Pharma (Inst); Lilly (Inst); Loxo/Lilly (Inst); Macrogenics (Inst); Mirati Therapeutics (Inst); Natera (Inst); Novartis (Inst); NovoCure (Inst); Sermonix Pharmaceuticals (Inst); Tersera (Inst); Thrive Earlier Detection Corp (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Agendia; Guardant Health; Tempus
 
Maria De Miguel
Honoraria - Janssen; MSD Oncology; Roche
(OPTIONAL) Uncompensated Relationships - Abbvie; Array BioPharma; Eisai; Genmab; Janssen; Lilly; MSD; Novartis; PharmaMar; Roche; Sanofi
 
Mor Tal Moskovitz
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; F. Hoffmann LaRoche; Genentech; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Boehringer Ingelheim; MSD; Novartis; Takeda
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer
 
Daniel Morgensztern
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; G1 Therapeutics; Gilead Sciences; PharmaMar; Takeda
Research Funding - Abbvie (Inst); Altum Pharmaceuticals (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); EpicentRx (Inst); Heat Biologics (Inst); Incyte (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Surface Oncology (Inst)
 
Shawn Jeffries
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Lan Wang
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Satwant Lally
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Christopher Conn
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Xiaohua Xin
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Edwin E. Jeng
Employment - Abbvie
Stock and Other Ownership Interests - Abbvie
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Achilles Therapeutics (Inst); Amgen (Inst); Association of Community Cancer Centers (ACCC) (Inst); Astellas Pharma (I); AstraZeneca (Inst); Atreca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Otsuka (I); Pfizer (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Hengrui Pharmaceutical (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Merck (Inst); Mirati Therapeutics (Inst); Neovia Oncology (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PMV Pharma (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); University of Michigan (Inst); WindMIL (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi